Meeting

Bitcoin falls in broad crypto pullback ahead of US Fed interest rate meeting

Leave a Comment / Crypto / By

Bitcoin fell along with Ether and all 10 other leading non-stablecoin cryptocurrencies during morning trading on Tuesday in Asia, erasing most of Monday’s gains. Cryptocurrencies followed overnight declines in U.S. stock markets as traders appeared to be taking profits ahead of this week’s Federal Reserve rate meeting and a slew of tech earnings. Solana led …

Bitcoin falls in broad crypto pullback ahead of US Fed interest rate meeting Read More »

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting.

Leave a Comment / Novel / By

Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting. Read More »

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

Leave a Comment / Novel / By

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting Read More »

Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting.

Leave a Comment / Novel / By

The oral presentation describes the unique library of APC nanobodies and its potential as a source for novel treatments of diseases including trauma, hemophilia, ischemia and sepsis. SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and …

Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting. Read More »